The present guidelines on the management of resectable non-small cell lung cancer (NSCLC) were formulated by the (ELCWP) in April 2005. They aim in answering the following eleven questions: 1) Is surgery the best therapy for a potentially resectable cancer? 2) How is complete resection defined? 3) Is systematic lymph node dissection necessary during surgery? 4) What is the role of radiotherapy after complete resec tion? 5) Should adjuvant or neoadjuvant chemotherapy be administered in clinical stages I or II? 6) Should adjuvant chemotherapy be administered in pathological stages I or II? 7) Is adjuvant therapy advisable after complete resection for pathologi cal stage IIIA N2? If yes, of what type: chemotherapy, radiotherapy or chemotradio ...
AbstractSurgical resection remains the standard of care for functionally operable early-stage non-sm...
BACKGROUND Stage II non-small cell lung cancer represents a heterogeneous group of diseases for whic...
Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years ha...
The present guidelines on the management of resectable non-small cell lung cancer (NSCLC) were formu...
The present guidelines on the management of unresectable non-metastatic non-small cell lung cancer (...
The present updated guidelines on the management of resectable non-small cell lung cancer (NSCLC) fo...
The present guidelines on the management of advanced non-small cell lung cancer (NS CLC) were formul...
The present updated guidelines on the management of unresectable non-metastatic nonsmall cell lung c...
Stage III N2 nonsmall cell lung cancer (NSCLC) is a complex disease with poor treatment outcomes. Fo...
These updated clinical practice guidelines on the treatment of advanced (metastatic disease) nonsmal...
The present guidelines on the management of extensive disease small cell lung cancer (SCLC) were for...
AbstractSurgical resection remains the standard of care for functionally operable early-stage non-sm...
BACKGROUND Stage II non-small cell lung cancer represents a heterogeneous group of diseases for whic...
Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years ha...
The present guidelines on the management of resectable non-small cell lung cancer (NSCLC) were formu...
The present guidelines on the management of unresectable non-metastatic non-small cell lung cancer (...
The present updated guidelines on the management of resectable non-small cell lung cancer (NSCLC) fo...
The present guidelines on the management of advanced non-small cell lung cancer (NS CLC) were formul...
The present updated guidelines on the management of unresectable non-metastatic nonsmall cell lung c...
Stage III N2 nonsmall cell lung cancer (NSCLC) is a complex disease with poor treatment outcomes. Fo...
These updated clinical practice guidelines on the treatment of advanced (metastatic disease) nonsmal...
The present guidelines on the management of extensive disease small cell lung cancer (SCLC) were for...
AbstractSurgical resection remains the standard of care for functionally operable early-stage non-sm...
BACKGROUND Stage II non-small cell lung cancer represents a heterogeneous group of diseases for whic...
Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years ha...